• Scientific rationale

    Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. 
    Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.
    As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more. New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.
    The 19th AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.

  • Programme

    10.00  Introduction to the ConferencePierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat
    Chairpersons: Maria Vittoria Dieci, Hesham Ahmed Gaballah Elghazaly
    10.30    Gene expression tools inbearly-stage HR+/HER2- breast cancer: when and which one?Gaia Griguolo
    11.00   Biological insights of the immune system in breast cancerModeratore: Maria Vittoria Dieci
    11.30    DNA NGS-based biomarkers in advanced breast cancer: how, where and which ones?Mafalda Oliveira
    12.00    Tackling diversity in HER2-positive breast cancer: biological and clinical implicationsTomas Pascual




    The changing relationship between locoregional recurrences and long-term outcomes
    Chairpersons: Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas
    14.00   Mapping local and regional recurrencesOrit Kaidar-person
    14.30    The surgical perspectiveModeratore: Eleftherios Mamounas
    15.00   Deciphering the EBCTCG meta-analysesPhilip Poortmans


    Multidisciplinary Tumor Board 1 – Locoregional treatmentPanelists: Bettina Borisch, Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas, Orit Kaidar-Person, Philip Poortmans, Hesham Ahmed Gaballah Elghazaly
    16.00  Clinical case 1. Skin flap thickness for IBR 
    16.15    Clinical case 2. When to resect/irradiate after systemic therapy for a recurrenceLuca Visani

    Clinical case 3: Local recurrence after DCIS 

    Eleonora Ferrara

     General discussion and concluding comments

    Jacek Jassem, Hesham Ahmed Gaballah Elghazaly


    17.15 Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2023 

    Lecture of the Awardee



    SESSION III – EARLY BREAST CANCER Chairpersons: Alessandra Gennari, Valentina Guarneri
    9.00     New therapeutic strategies in very young women: lights and shadowsAngela Toss
    9.20Elderly patients: how old is too old in the contemporary scenarioLaura Biganzoli
    9.40    Neoadjuvant approach: rethinking the paradigm?Federica Miglietta
    10.00New ESMO GuidelinesValentina Guarneri
    10.20    Discussion

    Coffee break

    Multidisciplinary Tumor Board 2 - Early breast cancerPanelists: Maria Vittoria Dieci, Alessandra Gennari, Valentina Guarneri, Eleftherios Mamounas, Philip Poortmans
    11.15    Clinical case 1. Genomic test in premenopausal patientsDavide Massa
    11.30    Clinical case 2. Adjuvant CDK 4/6 in patients with potential clinical indication but with low genomic riskMichele Bottosso
    11.45    Clinical case 3. HER2+ cT1c N0: adjuvant or neoadjuvant?Ottavia Amato
    12.00    General discussion and concluding commentsModeratore: Alessandra Gennari


    Chairpersons: Giuseppe Curigliano, Pierfranco Conte
    13.30    HR+ disease: is there any preferred treatment sequence at the time of endocrine-resistance?Stephen Johnston
    14.00    HER2+ disease: from guidelines to a personalized approach based on tumor and patient characteristicsSandra Swain M
    14.30   Triple negative disease: something more than label indications to dictate treatment sequence?Hope Rugo


    Multidisciplinary Tumor Board 3 – Metastatic Breast Cancer Panelists: Pierfranco Conte, Giuseppe Curigliano, Stephen Johnston, Hope Rugo

    Clinical case 1. Visceral crisis

    Grazia Maria Vernaci

    Clinical case 2. Oligometastatic disease

    Cristina Falci
    16.00Clinical case 3. Leptomeningeal metastases
    Carlo Alberto Giorgi
    16.15   General discussion and concluding commentsHope Rugo
    16.30Take home messages and adjourn
    Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat

  • Faculty

    Pierfranco Conte VeneziaValentina Guarneri Padova
    Philip Poortmans Wolrijk-antwerp (Belgio)Aleix Prat Barcellona (Spagna)

    Ottavia Amato MilanoLaura Biganzoli Prato
    Bettina Borisch Geneva (Svizzera)Michele Bottosso Padova
    Giuseppe Curigliano MilanoMaria Vittoria Dieci Padova
    Hesham Ahmed Gaballah Elghazaly Cairo (Egitto)Cristina Falci Padova
    Eleonora Ferrara NovaraAlessandra Gennari Novara
    Oreste Davide Gentilini MilanoCarlo Alberto Giorgi Padova
    Gaia Griguolo PadovaJacek Jassem Gdansk (Polonia)
    Stephen Johnston Londra (Regno Unito)Orit Kaidar-person Ramat Gan (Israele)
    Sibylle Loibl Francoforte (Germania)Eleftherios Mamounas Orlando - Florida (Stati Uniti D'America)
    Davide Massa PadovaFederica Miglietta Padova
    Mafalda Oliveira Barcellona (Spagna)Tomas Pascual Barcellona (Spagna)
    Hope Rugo San Francisco (Stati Uniti D'America)Sandra Swain M Washington (Stati Uniti D'America)
    Angela Toss ModenaGrazia Maria Vernaci Padova
    Luca Visani Firenze

  • How to participate the meeting

    Enrollment in the course can only be done through the online procedure, no new registrations will be accepted at the congress venue.

  • Registration

    Participation registration fees

    • Quota di partecipazione intera € 120.00
    • Per specializzandi € 80.00

    For eligibility criteria and other information on reduced fees (if applicable), contact info.bologna@accmed.org.

    To participate in the event, it is necessary to complete the registration procedure (including payment of the applicable fee) by 16/09/2023. Payment can be made online exclusively with Credit Cards or Paypal.

    If the minimum number of participants is not reached, the Academy reserves the right to cancel the activity. In this case, Accademia will proceed with the appropriate communication and full refund of the participation fees.

    In case of withdrawal, please inform AccMed promptly. If the waiver occurs within the 10th day prior to the start date of the event, the amount paid will be returned with the deduction of 30%. If the waiver occurs after that deadline, no reimbursement will be provided.

  • CME Instructions

    To obtain CME credits, users must meet the following requirements:

    1. Their declared profession/specialization must correspond to those accredited for CME.
    2. They must attend at least 90% of the course.
    3. They must complete the online meeting evaluation form.
    4. They must pass the learning assessment test with at least 75% correct answers. Only one attempt is allowed.

    The learning assessment test and meeting evaluation form must be submitted within three days of the event.

    Please note that in order to access the learning assessment test, users must (A) register at the course venue and (B) submit the online meeting evaluation form.

    Certificate of attendance 
    To download the certificate of attendance, users must have registered at the course venue.
    If their attendance is less than 75% of the stated duration, the certificate will reflect the percentage of attendance.
    We strongly encourage users to keep track of their personal badge and the badge recordings by the AccMed personnel, it is users' responsibility to have their attendance recorded accurately.

  • Training objective

    Contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultraspecialistica, ivi incluse le malattie rare e la medicina di genere

  • Quality Report


    Iscritti: 107

    Click here to open the detailed quality report